Vishal Bhatnagar, Bindu Kanapuru, MD, Laura Fernandes, Ting-Yu Chen, Mallorie H. Fiero, Erica Horodniceanu, Nicole Gormley, MD, Catherine Lerro, Fatima Rizvi, Yuan-Li Shen, Felice Yang, Anna Barcellos, Andrew J. Belli, Eric Hansen, Ching-Kun Wang MD, Donna Rivera and Paul Kluetz
Research matters
When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
Dianne Pulte, MD, Kelly J. Norsworthy, MD, Laura Fernandes, Bindu Kanapuru, MD, Catherine Lerro, Fatima Rizvi, Jonathon Vallejo, Ph.D., Kun Wang, PhD, Joseph Wynne, MD, PhD, Anna Barcellos, Andrew J. Belli, Eric Hansen, Thomas Gwise, Ph.D., Paul Kluetz, Angelo De Claro, Ching-Kun Wang and Donna Rivera
William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang and Paul M. Barr
Prapti A. Patel, Fieke Hoff, Andrew J. Belli, Eric Hansen, Courtney Anderson, Anna Barcellos, Laura L. Fernandes, Heidi Foss, Ming He, Molly Schulte, Ching-kun Wang
Benjamin A.Derman, Andrew J.Bellib, Minoo Battiwalla, Mehdi Hamadani, Ankit Kansagra, Hillard M.Lazarus, Ching-KunWang
Review of the use of RWD in hematologic malignancies clinical trials. Explores the challenges and potential for expanding the use of RWD in clinical trials.
Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang
We investigated the outcomes of patients treated with venetoclax based combination therapies in a large cohort of patients in the real-world setting. Survival differences were observed in the different treatment arms with Ven/LDAC having the shortest OS and ven/dac and ven/HMA having comparable survival rates.
Derman BA, Belli AJ, Wang C-K et al.
Awan FT, Belli AJ, Hansen E et al.
Kansagra A, Hansen E, Belli AJ et al.
Data from 1719 patients was used to understand the underlying patient characteristics and optimal treatment sequence for patients with functional high risk disease in multiple myeloma. Patients with cytogenetic high-risk received first line SCT that provided the longest TTNT as compared to other treatments.
